Literature DB >> 16217346

Sexual dysfunction in women with hyperprolactinemia: a pilot study report.

Pinar Kadioglu1, Ayse Serap Yalin, Ozay Tiryakioglu, Nurperi Gazioglu, Gokhan Oral, Oner Sanli, Kadir Onem, Ates Kadioglu.   

Abstract

PURPOSE: Hyperprolactinemia is a common hormonal disorder in women that may affect the phases of female sexual function (FSD). We investigated sexual function in patients with hyperprolactinemia.
MATERIAL AND METHODS: A total of 25 women with primary hyperprolactinemia and 16 age matched voluntary healthy women who served as the as control group were evaluated with a detailed medical and sexual history, including a female sexual function index (FSFI) questionnaire and the Beck Depression Inventory. Serum prolactin, dehydroepiandrosterone sulfate, free testosterone, androstenedione, 17alpha-hydroxyprogesterone, estradiol, free thyroxin and thyrotropin were measured. These variables were compared statistically between the 2 groups.
RESULTS: Except for prolactin serum hormone levels in women with hyperprolactinemia were not different from those in the control group. The median total FSFI score was 23.40 (IQR 17.70 to 27.30) in the hyperprolactinemic group, whereas healthy women had a median total FSFI score of 31.10 (IQR 27.55 to 32.88, p < 0.0001). FSD was diagnosed in 22 of 25 patients (88%), while 4 of 16 healthy women (25%) had FSD (p = 0.03). Desire (p = 0.001), arousal (p < 0.0001), lubrication (p = 0.001), orgasm (p = 0.001), satisfaction (p = 0.07) and pain (p = 0.003) domain scores were also significantly lower in women with hyperprolactinemia. Total FSFI (p = 0.009, r = -0.405), desire (p = 0.001, r = -0.512), arousal (p = 0.002, r = -0.466), orgasm (p = 0.026, r = 0.348) and satisfaction (p = 0.041, r = -0.320) scores negatively correlated with mean prolactin but not with the other hormones measured.
CONCLUSIONS: A significant percent of women with hyperprolactinemia whom we evaluated had sexual dysfunction. No hormonal changes other than prolactin and no depression was found as a cause of FSD.

Entities:  

Mesh:

Year:  2005        PMID: 16217346     DOI: 10.1097/01.ju.0000176456.50491.51

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Influence of dynorphin on estradiol- and cervical stimulation-induced prolactin surges in ovariectomized rats.

Authors:  Andrea M Stathopoulos; Cleyde V Helena; Ruth Cristancho-Gordo; Arturo E Gonzalez-Iglesias; Richard Bertram
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

Review 2.  Growth hormone, prolactin, and sexuality.

Authors:  M Galdiero; R Pivonello; L F S Grasso; A Cozzolino; A Colao
Journal:  J Endocrinol Invest       Date:  2012-09       Impact factor: 4.256

3.  Vitamin D3 deficiency is associated with female sexual dysfunction in premenopausal women.

Authors:  Masum Canat; Lütfi Canat; Feyza Yener Öztürk; Hatice Eroğlu; Hasan Anıl Atalay; Yüksel Altuntaş
Journal:  Int Urol Nephrol       Date:  2016-08-13       Impact factor: 2.370

4.  Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study.

Authors:  Robert Krysiak; Agnieszka Drosdzol-Cop; Violetta Skrzypulec-Plinta; Bogusław Okopien
Journal:  Endocrine       Date:  2016-02-22       Impact factor: 3.633

5.  Role of hormones in hypoactive sexual desire disorder and current treatment.

Authors:  Ahmed AlAwlaqi; Houda Amor; Mohamed E Hammadeh
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-12-15

6.  Comparison of the effect of Elaeagnus angustifolia flower capsule and sildenafil citrate tablet female sexual interest/arousal disorder in clinical trial study.

Authors:  Sanaz Zeinalzadeh; Abdol Ali Mohagheghzadeh; Fatemeh Ahmadinezhad; Marzieh Akbarzadeh
Journal:  J Family Med Prim Care       Date:  2019-11-15

7.  Changes of androgens levels in menopausal women.

Authors:  Maria Brzozowska; Andrzej Lewiński
Journal:  Prz Menopauzalny       Date:  2021-01-07

8.  Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.

Authors:  Hong Liu-Seifert; Bruce J Kinon; Christopher J Tennant; Jennifer Sniadecki; Jan Volavka
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.